KAI Pharmaceuticals, Inc. Expands KAI-1678 Development Program, Initiating a Phase 2a Study for Neuropathic Pain

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has initiated a second Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has begun enrollment of patients for the treatment of chronic neuropathic pain associated with chronic postherpetic neuralgia (PHN). In December 2008, KAI announced the initiation of its first Phase 2a study of KAI-1678 in patients with moderate-to-severe postoperative pain following total hip or total knee replacement.

Back to news